Zenith Drugs Board of Directors
Get the latest insights into the leadership at Zenith Drugs. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Sandeep Bhardwaj | Managing Director |
| Mr. Ranjana Sureshkumar Sehgal | Independent Director |
| Mr. Deendayal Kumawat | Independent Director |
| Mr. Anil Malik | Non Executive Director |
| Mr. Bhupesh Soni | Director |
| Mr. Ajay Singh Dassundi | Director |
Zenith Drugs Share price
ZENITHDRUG
70.95
0.35 (0.50%)NSE
BSE
Last updated on 4 Sep, 2025 | 15:02 IST
BUYSELL
Today's High
70.95
Today's Low
67.70
52 Week Low
47.15
52 Week High
154.40
The current prices are delayed, login to your account for live prices
LoginZenith Drugs FAQs
The board at Zenith Drugs consists of experienced professionals, including Mr. Sandeep Bhardwaj , Mr. Ranjana Sureshkumar Sehgal , and others, overseeing the company’s strategic and corporate governance.
Directors at Zenith Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Sandeep Bhardwaj is the current chairman at Zenith Drugs.
Executive directors at Zenith Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Zenith Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Zenith Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.